Poppy Love Views & Reviews

Total Page:16

File Type:pdf, Size:1020Kb

Poppy Love Views & Reviews VIEWS & REVIEWS What has changed in medical practice Poppy love that patients in 2008 seem to be in so much more pain than in 1988? PERSONAL VIEW Janet Gillespie I spread out the crumpled note the patient as a sedative and in larger doses as a powerful ber to December 2006 show that prescribing had given me while he spoke: he had been painkiller. People bought it in much the same of opioids rose by 62%, accounting for 25% to the pain clinic “for his back,” and they had way as they buy aspirin today: opium was of all analgesic prescribing (www.ppa.org.uk/ recommended this to help his pain. If he took more widely available in 1870 than tobacco news/pact-032007.htm). Notably, morphine the note to his (implied) trusty GP, he or she was a century later. Patent medicines such as prescribing rose by 57%. would sort it out for him; and if the treatment Dover’s powder were kept in the kitchen cup- Over my professional lifetime I have was unsuccessful, the pain clinic suggested, he board. Godfrey’s Cordial or Street’s Infants’ witnessed the consequences of iatrogenic could be referred to a neurosurgeon for assess- Quietness not only reduced colic in infants benzodiazepine dependency, these drugs ment. Mercifully, the trade name was scrawled but made it easier to sedate children so that having originally been promoted as a safer in block capitals. The British National Formulary they were indeed “seen and not heard.” The substitute for barbiturates. This was yet another revealed it to be a methadone transdermal intoxicant effects of opium were also appreci- example of the British love of problem solving patch. ated: one Ely brewer added it at source. by substitution: Wellington’s Beer Act (1830) I sat back and considered the matter. It was As early as the 1830s, however, it was recog- promoted beer to solve the misuse of gin, a not an entirely unreasonable suggestion: the nised that opium use reduced life expectancy, drink that was first promoted by William III patient was already taking paracetamol, tra- and by the 1860s it had become a matter of to reduce the wine trade with France, the old madol, and amitriptyline, with only moderate national concern. A third of all fatal poisonings enemy. So what are we prescribing opiates as control, and his sleep was still disturbed. What were opium related, and accidental poisonings a substitute for? Since the rise in opiate use surprised me was that the opiate prescrip- were so common that information leaflets were clearly predates the “loss” of co-proxamol, is tion had come before a referral for a surgical published to warn of the risks. The 1868 Poi- our prescribing a substitute for action? What opinion. sons and Pharmacy Act listed opium as one of has changed in medical practice that patients in In the mid-1980s, when I trained as a gen- 15 poisons whose use became restricted, but 2008 seem to be in so much more pain than in eral practitioner, opiate patches were only it wasn’t until 1920 that Britain had its first for- 1988, when treatments were fewer and surgical the proverbial twinkle in a pharmacologist’s mal legislation on the regulation of drugs, with techniques less refined? eye, and use in the community of “Bromp- the Dangerous Drugs Act. Today, we practise Or have the opiates ton cocktail” was considered avant-garde. Ten in the shadow of now become an end in years later, when I left the partnership, syringe Harold Shipman themselves—an easy, drivers and Macmillan nurses had become a and his profli- computer generated routine part of the primary healthcare serv- gate opiate mis- solution with the ice. But that was for terminal care; pain that use. It is somewhat slight annoyance of con- merited further investigation or had a possible paradoxical, then, that stipation and the benefits alternative solution was managed by an appro- prescriptions for opiates are of a mildly sedated patient? priate referral. now computer generated for If so, our profession is at risk of Perhaps part of the reason for this reluctance accuracy and legibility but by this sleepwalking into another iatrogenic to prescribe opiates was the need to handwrite method are less onerous to issue. dependency and forgetting the age old miser- prescriptions for “controlled drugs” in words I recently returned to general practice ies of opiate addiction. and figures. Individual doses were easily after a break of seven years and was My patient and I discussed the pain clinic’s remembered: scripts were for small amounts struck by the large number of opiate recommendation and assessed the risks and were therefore often repeated. In the days prescriptions. The NHS’s Prescription and benefits of such an action. He left with before computer searches, a straw poll of the Pricing Division confirms this increase: a prescription for opiates, and I am writ- partners would have produced a complete list from 2000 to 2005 the largest ing to expedite his assessment by of all patients taking opiates regularly. increase in painkiller pre- a neurosurgeon. That just Opiate prescribing dates back to Sir Tho- scribing was in opioid leaves the matter of our mas Sydenham, who, in the 1660s, promoted analgesics, with mor- poppy love. laudanum (from the Latin “laudare,” to praise), phine prescription Janet Gillespie is salaried a tincture of opium and alcohol. Writing at the increasing by 32% general practitioner, Buntingford end of the 19th century, William Osler called it and fentanyl patches Medical Centre, Buntingford, “God’s own medicine.” For the first time there nearly sixfold. This Hertfordshire gillespie. was a reliable means of controlling diarrhoeal trend continues: [email protected] symptoms, while in moderate doses it acted data from Octo- Cite this as: BMJ 2008;337:a2334 BMJ | 8 NOVEmbER 2008 | VOLUME 337 1115 VIEWS & REVIEWS A fat chance FROM THE I always enjoyed the university annual eating competi- already exist, and they are neither new nor complex. FRONTLINE tions: five contestants at the zenith of their ability, swal- We need to restore to people’s lives a balance between lowing whole pickled onions or boiled eggs, but only energy input and output. The scale of the problem, how- Des Spence one winner. Gluttony was celebrated, and like many ever, requires a political, not a medical, change. young people I never believed I would gain weight. But We have a decaying and neglected food culture, with times change. Obesity is now common in the young and families offering just readymade meals amid unconvinc- endemic to epidemic in adults. When we won the battle ing excuses of “pressure of time.” But the key problem is for wealth we lost the war of contentment. Doctors have our sedentary life. Current recommendations on activity foolishly rushed into this haemorrhaging of happiness. are woefully low, reflecting a poverty of expectation. Obesity is now a big medical business, with a rapid And the education system is so fevered with targets it is expansion in the number of specialist clinics. Likewise blind to our national disgrace: inactive children. Further- drug companies are active, lurking behind advocacy more, we are so plagued by spectres of mistrust that our groups that endorse drug treatment as a solution to the children are kept virtual prisoners indoors. irresistibly personalised pain of obese people. Recently, An urgent and fundamental change of infrastructure however, rimonabant, a cannabinoid receptor antagonist and schools policy is needed. We need to create safe anti-obesity drug, joined the long list of withdrawn drugs places for our children to play in, to allow them to cycle, (BMJ 2008;337:a2301). An all too familiar tale was the pedestrianised streets and to restrict car use, along with unforeseen side effects of the drug. education and financial incentives to get people to pre- We must stop the medical advance on obesity and pare food themselves. Medical interventions will serve bring the troops home, for once again we are destabilising only as an irrelevant policy distraction and have a fat self control and personal responsibility. Medicine alone chance of working. cannot solve the problem of obesity, and nor should Des Spence is general practitioner, Glasgow [email protected] it try—obesity is not an illness or syndrome. Solutions Cite this as: BMJ 2008;337:a2432 The bottom line StARTING OUT “I’ve just passed a 12 inch stool,” to irritable bowel syndrome approach. Time spent regularly Kinesh Patel said the voice over the telephone (gastroenterology seems to have with a patient is largely regarded as with a degree of solemnity more than its fair share). “waste” time that could have been commensurate with such a The bottom line is we’re not very used to see a new referral, thereby statement. “Is that normal?” good at assessing patients’ mental keeping the hallowed “follow-up “Well, I’m not sure,” replied state, let alone offering appropriate to new ratio” (abbreviated, rather the secretary, a little baffled as to treatment for their conditions. It ironically, to FUN) within target. what the appropriate response is much easier to comment matter And while I have no doubt was to such a question, while no of factly on the large ulcerating that such reforms have led to doubt at the same time wondering carcinoma you’ve discovered than shorter waiting times for patients why anyone would bother to to explore environmental influences with organic disease, those with measure a stool, let alone share that on diseases affecting the human debilitating conditions that do not information with anyone else. condition. fit neatly into any pathologically Although such an anecdote Patients with cancer need surgery, proved diagnosis have surely makes us snigger quietly to chemotherapy, and emotional suffered as they are bounced from ourselves, it does illustrate how support, whereas those with hospital to GP and then back again.
Recommended publications
  • Nsaids in Cats
    ISFM and AAFP Consensus Guidelines Long-term use of NSAIDs in cats Clinical Practice A preprint from the Journal of Feline Medicine and Surgery Volume 12, July 2010 Journal of Feline Medicine and Surgery (2010) 12, 519 doi:10.1016/j.jfms.2010.05.003 EDITORIAL NSAIDs and cats – it’s been a long journey Although the first This issue of JFMS contains the first ever panel have covered much valuable ground: international consensus guidelines ✜ To set the scene they consider how use of NSAIDs on the long-term use of non-steroidal common chronic pain can be in cats, typically was probably anti-inflammatory drugs (NSAIDs) in cats. related to degenerative joint disease, This timely publication, which appears on idiopathic cystitis, trauma and cancer. by Hippocrates, pages 521–538 (doi:10.1016/j.jfms.2010.05.004), ✜ They then explain how and why NSAIDs is a collaborative enterprise by the International can have such positive and, potentially, it has taken until Society of Feline Medicine (ISFM) and negative actions. now for cats to American Association of Feline Practitioners ✜ They consider the best ways of enhancing (AAFP). It has been compiled by a panel of owner and cat compliance, make suggestions gain the benefit of world leaders in the understanding of pain about sensible dosing frequencies, timing of in cats and, without doubt, is essential reading medication and accuracy of dosing, and the long-term use for all small animal veterinary surgeons. emphasize the importance of always using of these drugs. It is interesting to reflect that although the ‘lowest effective dose’.
    [Show full text]
  • List of Withdrawn Drugs
    List of withdrawn drugs WRITEN BY LAIMA JONUSIENE To prove that the drug companies make mistakes with our lives we publish this list. Drugs are rushed onto the market for profit. The testing of the drugs is on the major indication. Side effects are NOT tested pre and post. Side effects are observed NOT tested. The expense of pre and post side effect testing is astounding. So it is not done. Side effects are then seen in the public use and a drug is removed from the market after killing or hurting people. There is a special law that prohibits you from suing a drug company for damages unless you can prove they knew it was harmful and sold it anyway. This means there is even less need to test side effects and or report them during the testing process. https://www.youtube.com/watch?v=h7Sd0uBc6eE - How a drug pill is brought to the market. Some drugs have been withdrawn from the market because of risks to the patients. Usually this has been prompted by unexpected adverse effects that were not detected during Phase III clinical trials and were only apparent from postmarketing surveillance data from the wider patient community. This list is not limited to drugs that were ever approved by the FDA. Some of them (Lumiracoxib, Rimonabant, Tolrestat, Ximelagatran and Zimelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the U.S., when side effects became clear and their developers pulled them from the market. Likewise LSD was never approved for marketing in the U.S.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • The Use of a Subanesthetic Infusion of Intravenous Ketamine to Allow Withdrawal of Medically Prescribed Opioids in People with Chronic Pain, Opioid Tolerance And
    bs_bs_banner Pain Medicine 2012; 13: 1524–1525 Wiley Periodicals, Inc. The Use of a Subanesthetic Infusion of Intravenous Ketamine to Allow Withdrawal of Medically Prescribed Opioids in People with Chronic Pain, Opioid Tolerance and Hyperalgesia: Outcome at 6 Monthspme_1486 1524..1525 To the Editor, prior to detoxification. None of the patients had dorsal column stimulators or pumps. The problems of opioid tolerance [1], hyperalgesia (and other side effects of prescribed opioids), and the difficul- The questionnaire involved patients scoring five questions ties involved with opioid withdrawal, are rapidly becoming on an analogue scale from 0 (disagree) through to 5 an enormous health problem. Ketamine, in addition to the (strongly agree). Patients were asked whether they had potential to reduce pain for some weeks or months any further comments regarding the treatment, and to give postinfusion [2], has been shown to ameliorate symptoms a list of current medications (Table 1). of opioid withdrawal [3]. The responses show that: Patients with chronic pain taking medically prescribed opioids who had developed opioid-related tolerance and • While having the infusion was not pleasant, it was tol- probable hyperalgesia were admitted for 5 days of sub- erated by most. anesthetic infusion of ketamine to assist in complete with- • The patients felt better initially. drawal of opioids.1 The aim was to withdraw all opioid • Eight of 11 continued to feel better at 2 months. medication for a period of at least 2 weeks to allow toler- • At 6 months, three of the patients continued to feel well ance to minimize and review progress over 6 months.
    [Show full text]
  • FDA Briefing Document
    1 FDA Briefing Document Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting February 12, 2019 Agenda Topic: The committees will discuss the efficacy, safety, and risk-benefit profile of New Drug Application (NDA) 211243, esketamine 28 mg single-use nasal spray device, submitted by Janssen Pharmaceuticals, Inc., for the treatment of treatment-resistant depression 2 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought New Drug Application 211243, esketamine for the treatment of treatment-resistant depression to this Advisory Committee to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory
    [Show full text]
  • The NCGC Pharmaceutical Collection
    PERSPECTIVE PHARMACOLOGY indications (such as in the case of pregaba- lin, an antiepileptic drug that was also found The NCGC Pharmaceutical Collection: to be useful for treating neuropathic pain) (6–8) or the withdrawal of marketing autho- A Comprehensive Resource of Clinically rization (which occurred for fen uramine, originally used to suppress appetite but Approved Drugs Enabling Repurposing and then found to lead to cardiotoxicity) (9, 10). Extension of the clinical use of a drug to a Chemical Genomics new indication has historically occurred via serendipitous clinical observation (for ex- Ruili Huang,* Noel Southall,* Yuhong Wang, Adam Yasgar, Paul Shinn, ample, the observation that sildena l, which Ajit Jadhav, Dac-Trung Nguyen, Christopher P. Austin was developed for treating hypertension, was also useful for treating erectile dysfunc- Small-molecule compounds approved for use as drugs may be “repurposed” for new tion) but more recently has occurred via a indications and studied to determine the mechanisms of their bene cial and adverse logical connection of a disease’s pathophysi- e ects. A comprehensive collection of all small-molecule drugs approved for human ology to a drug’s target. Examples of this sce- use would be invaluable for systematic repurposing across human diseases, particularly nario include (i) losartan, a drug developed for rare and neglected diseases, for which the cost and time required for development of a new chemical entity are often prohibitive. Previous e orts to build such a compre- to treat hypertension that might also be use- hensive collection have been limited by the complexities, redundancies, and semantic ful for treating Marfan syndrome because of inconsistencies of drug naming within and among regulatory agencies worldwide; a lack its e ects on transforming growth factor–β, of clear conceptualization of what constitutes a drug; and a lack of access to physical which plays a role in this condition, and (ii) samples.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT TOLFEDOL, 40 mg/ml, solution for injection for cattle, pigs, cats and dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Tolfenamic acid ……………………………………………… 40 mg Excipients: Benzyl alcohol (E1519)… …… … …… … …… … …… … …… ..10.4 mg Sodium formaldehyde sulphoxylate………………………….. 5 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. A clear yellowish solution. 4 CLINICAL PARTICULARS 4.1 Target Species Cattle, pigs, cats and dogs. 4.2 Indications for use, specifying the target species In cattle, as an adjunct in the treatment of pneumonia by improving general conditions and nasal discharge and as an adjunct in the treatment of acute mastitis. In pigs, as an adjunct in the treatment of Metritis Mastitis Agalactia syndrome. In dogs : for the treatment of inflammation associated with musculo-skeletal disorders and for the reduction of post-operative pain. In cats : as an adjunct in the treatment of upper respiratory disease in association with antimicrobial therapy, if appropriate. 4.3 Contraindications Do not use in cases of cardiac disease. Do not use in cases of impaired hepatic function or acute renal insufficiency. Do not use in cases of ulceration or digestive bleeding, in case of blood dyscrasia. Do not inject intramuscularly in cats. Do not use in known cases of hypersensitivity to the active substance or to any of the excipients. Do not use in dehydrated, hypovolaemic or hypotonic animals (due to its potential risk of increasing renal toxicity). Do not administer other steroidal or non – steroidal anti – inflammatory drugs concurrently or within 24 hours of each other.
    [Show full text]
  • Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market
    RESEARCH ARTICLE Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market Kye Hwa Lee1, Su Youn Baik1, Soo Youn Lee1, Chan Hee Park1, Paul J. Park3, Ju Han Kim1,2* 1 Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul 110799, Korea, 2 Biomedical Informatics Training and Education Center (BITEC), Seoul National University Hospital, Seoul 110744, Korea, 3 Department of a11111 Physiology and Cell Biology, University of Nevada School of Medicine, Reno, Nevada, United States of America * [email protected] Abstract OPEN ACCESS Despite substantial premarket efforts, a significant portion of approved drugs has been Citation: Lee KH, Baik SY, Lee SY, Park CH, Park PJ, Kim JH (2016) Genome Sequence Variability withdrawn from the market for safety reasons. The deleterious impact of nonsynonymous Predicts Drug Precautions and Withdrawals from substitutions predicted by the SIFT algorithm on structure and function of drug-related pro- the Market. PLoS ONE 11(9): e0162135. teins was evaluated for 2504 personal genomes. Both withdrawn (n = 154) and precaution- doi:10.1371/journal.pone.0162135 ary (Beers criteria (n = 90), and US FDA pharmacogenomic biomarkers (n = 96)) drugs Editor: Jinn-Moon Yang, National Chiao Tung showed significantly lower genomic deleteriousness scores (P < 0.001) compared to others University College of Biological Science and Technology, TAIWAN (n = 752). Furthermore, the rates of drug withdrawals and precautions correlated signifi- cantly with the deleteriousness scores of the drugs (P < 0.01); this trend was confirmed for Received: April 7, 2016 all drugs included in the withdrawal and precaution lists by the United Nations, European Accepted: July 22, 2016 Medicines Agency, DrugBank, Beers criteria, and US FDA.
    [Show full text]
  • A Machine Learning Approach Predicts Tissue-Specific Drug Adverse 2 Events 3 4 Neel S
    bioRxiv preprint doi: https://doi.org/10.1101/288332; this version posted March 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 A Machine Learning Approach Predicts Tissue-Specific Drug Adverse 2 Events 3 4 Neel S. Madhukar*1,2,3,4, Kaitlyn Gayvert*1,2,3,4, Coryandar Gilvary1,2,3,4, Olivier Elemento1,2,3,4 5 6 1 HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Dept. of 7 Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA; 8 2 Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 9 10065, USA; 10 3 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA; 11 4 Tri-Institutional Training Program in Computational Biology and Medicine, New York, NY 10065, USA; 12 13 * co-first authors 14 15 Correspondence: Olivier Elemento ([email protected]) 16 17 ABSTRACT 18 19 One of the main causes for failure in the drug development pipeline or withdrawal post 20 approval is the unexpected occurrence of severe drug adverse events. Even though such 21 events should be detected by in vitro, in vivo, and human trials, they continue to 22 unexpectedly arise at different stages of drug development causing costly clinical trial 23 failures and market withdrawal. Inspired by the “moneyball” approach used in baseball to 24 integrate diverse features to predict player success, we hypothesized that a similar 25 approach could leverage existing adverse event and tissue-specific toxicity data to learn 26 how to predict adverse events.
    [Show full text]
  • Correlation Between Drug Market Withdrawals and Socioeconomic, Health, and Welfare Indicators Worldwide
    ORIGINAL ARTICLE Medicine General & Social Medicine http://dx.doi.org/10.3346/jkms.2015.30.11.1567 • J Korean Med Sci 2015; 30: 1567-1576 Correlation between Drug Market Withdrawals and Socioeconomic, Health, and Welfare Indicators Worldwide Kye Hwa Lee, Grace Juyun Kim, The relationship between the number of withdrawn/restricted drugs and socioeconomic, and Ju Han Kim health, and welfare indicators were investigated in a comprehensive review of drug regulation information in the United Nations (UN) countries. A total of of 362 drugs were Seoul National University Biomedical Informatics withdrawn and 248 were restricted during 1950-2010, corresponding to rates of 12.02 ± (SNUBI) and Systems Biomedical Informatics ± ± Research Center, Division of Biomedical Informatics, 13.07 and 5.77 8.69 (mean SD), respectively, among 94 UN countries. A Seoul National University College of Medicine, socioeconomic, health, and welfare analysis was performed for 33 OECD countries for Seoul, Korea which data were available regarding withdrawn/restricted drugs. The gross domestic product (GDP) per capita, GDP per hour worked, health expenditure per GDP, and elderly Received: 23 April 2015 Accepted: 10 July 2015 population rate were positively correlated with the numbers of withdrawn and restricted drugs (P < 0.05), while the out-of-pocket health expenditure payment rate was negatively Address for Correspondence: correlated. The number of restricted drugs was also correlated with the rate of drug-related Ju Han Kim, MD deaths (P < 0.05). The World Bank data cross-validated the findings of 33 OECD countries. Division of Biomedical Informatics, Systems Biomedical Informatics Research Center, Seoul National University College The lists of withdrawn/restricted drugs showed markedly poor international agreement of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea between them (Fleiss’s kappa = -0.114).
    [Show full text]
  • Cheminformatics Approaches to Drug Discovery: from Knowledgebases to Toxicity Prediction and Promiscuity Assessment
    Cheminformatics Approaches to Drug Discovery: From Knowledgebases to Toxicity Prediction and Promiscuity Assessment Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by VISHAL BABU SIRAMSHETTY from Hyderabad, India 2018 This research work was conducted from December 2014 to June 2018 under the supervision of PD Dr. Robert Preissner at the Charité – Universitätsmedizin Berlin. 1. Reviewer: PD Dr. Robert Preissner (Charité – Universitätsmedizin Berlin) 2. Reviewer: Prof. Dr. Gerhard Wolber (Freie Universität Berlin) Date of defense: 09.01.2019 Acknowledgements I would like to take this opportunity to thank all those people who have accompanied me during the last years and contributed in many ways to the completion of this dissertation. Firstly, I would like to thank my supervisor PD Dr. Robert Preissner for his guidance, encouragement, and support throughout my doctoral study. The last four years had a significant impact on my life. I believe I evolved as a researcher as well as a social human being. I feel privileged to participate in international conferences, meet some pioneers in the field and present my work. Dear Robert, I sincerely thank you for providing the freedom to explore my interests and the trust you placed on me. I would also like to thank Prof. Dr. Gerhard Wolber for being the co-referent of my thesis. I extend my gratitude to all my colleagues of the Structural Bioinformatics Group at Charité for being so kind and for providing a friendly and interactive working atmosphere. Many thanks to Malgorzata Drwal, Priyanka Banerjee, Andreas Oliver Eckert, Björn Oliver Gohlke, and Janette Nickel-Seeber for the highly productive and pleasant collaborations within the group.
    [Show full text]